How Do SGLT-2 Inhibitors Work to Prevent Heart Failure?

JACC Heart Fail. 2020 Jan;8(1):67-69. doi: 10.1016/j.jchf.2019.11.009.

Authors

Muthiah Vaduganathan¹, Brian L Claggett², Scott D Solomon³

Affiliations

¹ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: [email protected].
² Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: https://twitter.com/scottdsolomon.

PMID: 31896418
DOI: 10.1016/j.jchf.2019.11.009

No abstract available

Keywords: SGLT-2 inhibitors; heart failure; mediation analyses; trials.

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Canagliflozin
Diabetes Mellitus, Type 2*
Heart Failure*
Humans
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin